CERo Therapeutics Holdings, Inc. (CERO)
NASDAQ: CERO · Real-Time Price · USD
0.9358
+0.0108 (1.17%)
Apr 29, 2025, 1:03 PM EDT - Market open

CERO Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-8.3-7.29-0.67-0.54
Depreciation & Amortization
1.161.12--
Loss (Gain) From Sale of Investments
---0
Stock-Based Compensation
0.930.1--
Other Operating Activities
-8.54-0.25-2.84-0.03
Change in Accounts Payable
0.261.281.640.02
Change in Income Taxes
--0.6-
Change in Other Net Operating Assets
1.58-0.740.17-0.65
Operating Cash Flow
-12.92-5.79-1.09-1.2
Other Investing Activities
--180.84-306
Investing Cash Flow
--180.84-306
Short-Term Debt Issued
0.42-0.65-
Long-Term Debt Issued
-0.61--
Total Debt Issued
0.420.610.650.09
Short-Term Debt Repaid
-0.4---
Long-Term Debt Repaid
-0.02---
Total Debt Repaid
-0.42---0.09
Net Debt Issued (Repaid)
-00.610.65-
Issuance of Common Stock
4.810.01-315.21
Repurchase of Common Stock
---139.35-
Other Financing Activities
-0.53-0.04--6.14
Financing Cash Flow
13.730.57-138.7309.08
Net Cash Flow
0.81-5.2241.041.88
Levered Free Cash Flow
-3.669.9-13.44-
Unlevered Free Cash Flow
-3.669.9-13.44-
Change in Net Working Capital
-4.37-13.4811.63-
Updated Nov 20, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q